Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells > REFERENCE LIBRARY

본문 바로가기
커뮤니티

[EZ-Cytox] Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-…

김상진
2022-01-28 08:55 2,406 1

본문

년도
2021
제품명
EZ-Cytox
학술지명
Scientific Reports

Currently, there is no appropriate treatment option for patients with sorafenib-resistant hepatocellular carcinoma (HCC). Meanwhile, pronounced anticancer activities of newly-developed mitochondria-accumulating self-assembly peptides (Mito-FF) have been demonstrated. This study intended to determine the anticancer effects of Mito-FF against sorafenib-resistant Huh7 (Huh7-R) cells. Compared to sorafenib, Mito-FF led to the generation of relatively higher amounts of mitochondrial reactive oxygen species (ROS) as well as the greater reduction in the expression of antioxidant enzymes (P < 0.05). Mito-FF was found to significantly promote cell apoptosis while inhibiting cell proliferation of Huh7-R cells. Mito-FF also reduces the expression of antioxidant enzymes while significantly increasing mitochondrial ROS in Huh7-R cells. The pro-apoptotic effect of Mito-FFs for Huh7-R cells is possibly caused by their up-regulation of mitochondrial ROS, which is caused by the destruction of the mitochondria of HCC cells.

댓글목록1

김상진님의 댓글

김상진
2022-01-28 08:55
JournalImpactFactor(2019) : 3.998
카카오톡
이메일
견적/제품문의
샘플신청
게시판 전체검색